Trending Now
Gilead Sciences Inc. (NASDAQ:GILD) Announce $21 Billion Acquisition Of Cancer Drug...
Gilead Sciences Inc. (NASDAQ:GILD) has continued to boost its cancer portfolio with the latest announcement of the acquisition of Immunomedics Inc. (NASDAQ:IMMU)
Gilead enhancing oncology...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Advanced Micro Devices (NASDAQ:AMD) profit taking
AMD has had an amazing run over the last month on the back of positive analyst comments and the announcement of one...
MAKE IT MODERN
LATEST REVIEWS
Allogene Therapeutics Inc. (NASDAQ: ALLO) and Antion Biosciences announce Exclusive Global...
Allogene Therapeutics Inc. (NASDAQ: ALLO) and Swiss cell and gene engineering firm Antion Biosciences have announced the signing of an exclusive partnership and global...
MAKE IT MODERN
PERFORMANCE TRAINING
Harmonic Inc (NASDAQ: HLIT) Announces $2.1 Million in Income During The Second Quarter of...
Harmonic Inc (NASDAQ: HLIT) recently announced its unaudited results in 2Q2021. The company reported a revenue of $113.4 million, a 53% year-over-year increase.
Financial summary
According...
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) Enters Agreement For Exchange Of Senior Notes To Reduce Its...
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) has signed a privately-negotiated, separate exchange agreement with specific holders of the 5.25% Convertible Senior Notes that will be due...
TC BioPharm Ltd (NASDAQ: TCBP) Receives Approval to Begin OmnImmune Clinical Trial
TC BioPharm (NASDAQ: TCBP) has received approval from the Research Ethics Committee and MHRA to start a clinical trial on OmnImmune, which treats Acute...
Savara Inc. (SVRA): Progress in Rare Respiratory Disease Treatment with MOLBREEVI
Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company specializing in rare respiratory diseases, saw its stock close at $3.15 on December 27,...
IGM Biosciences, Inc. (IGMS): Significant Stock Surge Following Positive First-Quarter Results
IGM Biosciences, Inc. (NASDAQ: IGMS) recently saw a substantial increase in its stock price, closing at $11.47, up by 36.39% during regular...
MAKE IT MODERN
